|
|
Volumn 9, Issue 12, 2000, Pages 2935-2943
|
|
An assessment of iloperidone for the treatment of schizophrenia
|
|
Author keywords
Atypical antipsychotics; Dopamine receptors; Extrapyramidal syndromes; Iloperidone; Psychosis; Schizophrenia; Serotonin receptors
|
|
Indexed keywords
2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE;
ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL;
AMISULPRIDE;
CHOLINERGIC RECEPTOR;
CLOZAPINE;
DOPAMINE 1 RECEPTOR;
DOPAMINE 2 RECEPTOR;
DOPAMINE 2 RECEPTOR BLOCKING AGENT;
DOPAMINE 3 RECEPTOR;
DOPAMINE 4 RECEPTOR;
DOPAMINE 5 RECEPTOR;
DOPAMINE RECEPTOR BLOCKING AGENT;
EPLIVANSERIN;
GLUCURONIC ACID;
HALOPERIDOL;
HISTAMINE;
ILOPERIDONE;
MESSENGER RNA;
NEUROLEPTIC AGENT;
OLANZAPINE;
QUETIAPINE;
REMOXIPRIDE;
RISPERIDONE;
SEROTONIN;
SEROTONIN ANTAGONIST;
SEROTONIN RECEPTOR;
SERTINDOLE;
UNINDEXED DRUG;
ZIPRASIDONE;
ZOTEPINE;
AGRANULOCYTOSIS;
ANIMAL BEHAVIOR;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
APLASTIC ANEMIA;
ARTICLE;
CARDIOTOXICITY;
CLIMBING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOPAMINERGIC SYSTEM;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG MARKETING;
DRUG METABOLISM;
DRUG POTENCY;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG TOLERABILITY;
EXTRAPYRAMIDAL SYMPTOM;
HUMAN;
HYPOTENSION;
INCIDENCE;
MAJOR CLINICAL STUDY;
METABOLITE;
MOTOR DYSFUNCTION;
MOUSE;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
RAT;
SCHIZOPHRENIA;
SEROTONINERGIC SYSTEM;
SIDE EFFECT;
WEIGHT GAIN;
|
|
EID: 0033646827
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.9.12.2935 Document Type: Article |
|
Times cited : (32)
|
|
References (24)
|
